The most promising longevity drug isn't a peptide or metformin. It's the Shingles vaccine.
New data shows it slows biological aging and lowers systemic inflammation for 4+ years post-shot. We are seeing a 20% reduction in new dementia diagnoses and a 25% lower risk of stroke.
Stop waiting for a magic pill. One is already on the shelf.
Speaking today at NY Tech Week: Sick care is dead. What comes next?
Consumer health is already the new front door: AI, labs, GLP-1s, wearables, telehealth + longevity clinics.
The question is how we make it clinically useful, not just noisier.
RSVP: https://t.co/tdnFvEFCoM
PFOA-free ≠ PFAS-free.
PTFE-free is a stronger clue.
Ceramic can be useful but finite-life.
“Titanium” can mean very different things depending on the actual coating/surface.
@JeromeAdamsMD I always *sorta* joke that the next longevity test I want is a colonoscopy!
For real though, I think we need to move the screening age even younger given just one-half (50%) of colorectal cancer diagnoses under age 50 are in people 45-49 years...
@Austen also - why does everything think kids don't remember things from early life? I recall many memories from sub-5.
but even without declarative memory, the emotional impact on a child's outlook and relationship with their family members is so deeply impacted by such an experience.
@rand_longevity Good list. I’d add BP, waist/visceral adiposity, sleep quality, and Lp(a) once
ApoB + VO2 max + grip strength are the big ones for me because they’re predictive and actually actionable.
1/4 Speaking at NYC AI x Longevity Summit during NYC Tech Week on Jun 4–5.
I’m on the AI in Clinical Practice panel Thu 3:30–4:30p ET w/ @mishalreja, @NeilpDo + Jim Donnelly, hosted by @LongevityGL.
@DrDorisDay Much fun to reunite with fellow longevity physicians and brilliant speakers @agingdoc1, Dr. Jay Luthar, @MariZazzer@LongevityGL - can't wait till our next panel together 💪
Longevity medicine has a major bottleneck.
And it's not even the science.
It's care delivery.
Because most health decisions don’t happen in a doctor’s office.
Spent the last two days at the Aging Code Summit in Cambridge with scientists, founders, investors, and clinicians working across biomarkers, therapeutics, AI, neurodegeneration, inflammation, regenerative medicine, and clinical trials.
The discovery engine is real.
But as a practicing longevity clinician, I kept thinking about the layer after discovery:
How does any of this actually reach people?
Not just the patient with time, money, and medical literacy.
Not just the person who can find the right concierge doctor.
And not just once a year, during a visit.
People make health decisions every day: in grocery stores, gyms, group chats, supplement aisles, lab portals, algorithm feeds, and anxious 11pm searches.
Most of those moments do not involve a physician.
So if the future of longevity is “clone more doctors,” we’re going to fail.
There will never be enough of us. And that’s not how people live.
The real opportunity is to build better surfaces for healthcare:
- tools that translate evidence into action
- systems that support follow-through
- guardrails against overtesting, overtreatment, and false certainty
- care models that meet patients where they already are
That’s the part I care most about building.
Longevity needs great science.
It also needs delivery models that make the science usable. @gocarecore
Thanks so much to @LongevityGL for another amazing meeting, and fellow speakers, organizers, and attendees: @Mindvyne@3cubedAi@DrGlorioso@justinqtaylor@NeuroAgeTX@agingdoc1@usnehal@CoreViva@agelessrx_@kpfortney@bioagelabs@lifebiosciences@JamieHeywood@microbeminded2@polybioRF@mahdi_moqri@agingbiomarkers@manoliskellis@MIT_Picower@DrDorisDay@VincereBio@InSilicoMeds@hevolution_f@CellinoBio@MariZazzer
Delighted to meet the brilliant @DrDorisDay - skin is the absolute most visible aspect of longevity, for science and clinical application alike - fascinating work with blocking mTORC1!
@emollick I wonder how much feedback/training there is re the generic narrative structures used in modern stories (news, movies) further cementing these patterns
@agingdoc1@DrDorisDay Same here! Really enjoyed sharing the stage. These conversations are at their best when clinicians, longevity folks, and builders are actually in the same room wrestling with what’s ready for practice vs still hypothesis
@DrDorisDay@agingdoc1 Loved meeting you too, Doris. I so agree with your skin-as-a-window to health - thank you for presenting such a sharp bridge between aesthetics, prevention, and longevity!
The longevity field has gotten better at measuring aging.
Epigenetic clocks. Proteomics. VO2 max. DEXA. CGMs. ApoB. Inflammatory markers. Microbiome readouts. A growing menu of things we can track, score, compare, and optimize.
But a biomarker is not a treatment plan.
The harder question is clinical: when should any of that data actually change care?
That’s the lens I’m bringing to Aging Code Summit this week in Cambridge. I’ll be on the Wed May 27, 9:50am panel, “Longevity in Practice: Concierge Medicine and Frontline Learnings,” with Jay Luthar, @agingdoc1, and Marianna Zaslavsky.
What I’m most interested in:
- Which biomarkers are mature enough to act on
- Which interventions change outcomes, not just dashboards
- How to give high-agency patients better tools without handing them expensive noise
- Where concierge/longevity medicine can be more accountable, not just more personalized
If you’re in Boston/Cambridge for Boston Tech Week and thinking about how aging science makes the jump into real clinical care, come say hi.
Hosted by @LongevityGlobal with @Mindvyne and @3cubedAi, during Boston Tech Week.
Details and registration:
https://t.co/Jr5WK6a5YP
#BostonTechWeek #LongevityMedicine